Passez à l'illimité avec Magzter GOLD
Obtenez un accès illimité à plus de 9 000 magazines, journaux et articles Premium pour seulement
Essayer OR - Gratuit
Piramal Alternatives invests ₹110 cr in Biodeal Pharma
Mint Mumbai
|April 09, 2024
As contract manufacturing becomes the new A growth driver of the pharmaceutical industry, Piramal Alternatives, the fund management business of the Piramal Group, on Monday announced an investment of ₹110 crore in Biodeal Pharmaceuticals Ltd, a contract development and manufacturing organization.
The company in a filing disclosed that the deal is being facilitated through convertible instruments from its performing credit fund and will be directed towards improving infrastructure and capacities, upgrading tech, and nutraceuticals manufacturing facility.
Emkay Global was the exclusive financial advisor to Biodeal for this deal.
Piramal Alternatives is an institutional capital provider in India with a total of $1.5 bilmanagement.
Cette histoire est tirée de l'édition April 09, 2024 de Mint Mumbai.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Mint Mumbai
Mint Mumbai
Europe bets on $25 bn space budget amid defence hike
Europe’s equivalent of NASA is seeking €22 billion ($25.
1 min
November 27, 2025
Mint Mumbai
China’s ‘McNuggetization’: It’s beneficial for the environment
A wide-scope dietary shift in China is doing the planet a good turn
3 mins
November 27, 2025
Mint Mumbai
Flexi-cap funds in focus as smids falter
A silent pivot
3 mins
November 27, 2025
Mint Mumbai
Labour codes: Focus on empathy and not just efficiency
The consolidation of 29 archaic labour laws into four comprehensive new codes—on wages, social security, industrial relations and occupational safety—is among the most significant structural reforms undertaken by India in the post-liberalization era.
3 mins
November 27, 2025
Mint Mumbai
These firms will sell shovels during semaglutide gold rush
Weight-loss drug semaglutide, also used to treat type-2 diabetes, will face its next big turning point in early 2026, when patents held by Novo Nordisk expire in India.
2 mins
November 27, 2025
Mint Mumbai
HC to hear Apple's plea on fine in Dec
Apple is challenging the new penalty math formula in India's competition law.
1 min
November 27, 2025
Mint Mumbai
Climate crisis: Innovation works, compression doesn't
After weeks of hot air, the UN’s CoP summit limped to an end in Brazil's Amazonian hub of Belém over the weekend, with a ‘deal’ that delivers nothing measurable for the climate, while wasting political capital and much effort on pledges.
3 mins
November 27, 2025
Mint Mumbai
MO Alternates launches its maiden private credit fund
The %3,000 crore fund has drawn capital from family offices, ultra-HNIs and institutions
3 mins
November 27, 2025
Mint Mumbai
Kharif grain production likely to rise to 173 mt
India's kharif foodgrain output is expected to rise to 173.
1 min
November 27, 2025
Mint Mumbai
IL&FS group repays ₹48,463 cr loan
Debt-ridden IL&FS group has repaid ₹48,463 crore to its creditors as of September 2025, out of the total ₹61,000 crore debt resolution target, as per the latest status report filed before insolvency appellate tribunal NCLAT.
1 min
November 27, 2025
Listen
Translate
Change font size